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INTRODUCTION
Gastric cancer is one of the leading fatal malignancies
worldwide (1), and the most common malignancy in Korea
(2). Now, gastric cancer has been reported to be the second
leading cause of death due to malignancy in Korea, which
was the first leading cause before 2005 (2). However, the
etiology of gastric cancer has not yet been unveiled comple-
tely, and the previous studies have provided evidence that
risk factors such as diet, infection including Helicobacter pylori
and Epstein-Barr virus, and hereditary trait may be involved
in (3). Recently, accumulation of molecular events has been
known to be important in the development of gastric cancer
(4). Furthermore, these biological markers as well as tradi-
tional histopathological parameters can be used as prognos-
tic factors (4-8).
It was suggested that beta-catenin can regulate NF-kap-
paB negatively (9), and our previous study revealed that NF-
kappaB nuclear positivity was more frequent in Epstein-
Barr virus (EBV)-positive gastric carcinomas than conven-
tional gastric carcinomas (10).
Beta-catenin, a 92-kDa protein (11), plays multifunction-
al roles. First, beta-catenin is a component of the cell-cell
adhesion complex, as an E-cadherin/beta-catenin complex.
Secondly, beta-catenin acts as a coactivator of transcription
factors involved in the Wnt signaling pathway (11). Wnt sig-
naling is mediated by secreted proteins that interact with
specific cell-membrane receptors and is involved in the growth
and differentiation of cells during development. Wnt path-
way dysregulation has been implicated in many cancers (11).
Uncontrolled activation of this signaling pathway may in-
duce inappropriate proliferation of target cells and may con-
tribute to the development of malignancy. Dysfunction of
this regulatory pathway may result in the accumulation of a
hypophosphorylated stable form of beta-catenin in the cyto-
plasm (11), from whence it translocates to the nucleus, bind-
ing to the high mobility group domain factors Tcf/LEF (12)
and stimulating transcription of target genes such as c-myc
and cyclin D1 (13).
E-cadherin is a 120-kDa transmembrane glycoprotein that
is responsible for calcium-dependent intercellular adhesion
by homotypic interactions (14), and hence plays a critical
role in cancer cell metastasis and invasion because anchorage
of cells to substrate is critical for the integrity of many cell
types including epithelial cells. Becker et al. first disclosed
that E-cadherin is implicated in gastric carcinogenesis (15).
Functional cadherin-dependent cell adhesion requires the
formation of complexes between E-cadherin and catenins.
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Epstein-Barr Virus, Beta-Catenin, and E-cadherin in Gastric Carcinomas
Activated beta-catenin is suggested to inhibit NF-kappaB activation, and we previ-
ously demonstrated that NF-kappaB nuclear positivity was more frequent in Epstein-
Barr virus (EBV)-infected gastric carcinomas. It is controversial that beta-catenin
and E-cadherin are prognostic markers in gastric carcinomas. To define a relation-
ship between beta-catenin and EBV, and the prognostic value of beta-catenin and
E-cadherin, we analyzed in situ hybridization for EBV-encoded small RNAs, beta-
catenin, and E-cadherin immunohistochemistry, and clinicophatological features in
111 gastric carcinomas. EBV infection was detected in seven carcinomas (6.3%);
none of seven showed beta-catenin nuclear accumulation, and five out of seven
revealed beta-catenin membranous loss or cytoplamic expression. Eighty cases
(72.1%) showed beta-catenin alteration; i.e., loss of membrane staining in 65 (58.6
%), cytoplasmic expression in 35 (31.5%), and nuclear accumulation in 15 (13.5%).
E-cadherin alteration was observed in 34 cases (30.6%) and correlated with beta-
catenin alteration. On multivariate analysis, the combined immunoexpression group
of beta-catenin nuclear accumulation/ E-cadherin alteration and the advanced TNM
cancer stage group showed poor patient’s survival (p<0.05). In conclusion, beta-
catenin activation through nuclear accumulation hardly occurred in EBV-infected
gastric carcinomas. The combined immunoexpression pattern of beta-catenin and
E-cadherin can be used as a prognostic marker in gastric carcinomas. 
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However, cell growth suppressor activity of E-cadherin is
not adhesion-dependent. E-cadherin protein can directly
transduce a growth inhibitory signal, through the inhibi-
tion of beta-catenin signaling (16). 
Previous immunohistochemical studies have shown a close
relationship between alteration of E-cadherin or bata-catenin
and lower 5-yr survival rates in diverse human cancers such
as breast, urinary bladder, prostate, and esophagus cancer
(17-20). However, there is a conflict concerning the prog-
nostic significance of bata-catenin or E-cadherin in gastric
cancer (5-8, 21-23). 
In the present study, we investigated in situ hybridization
for EBV-encoded small RNAs and immunoexpression of
beta-catenin and E-cadherin proteins in 111 cases of gastric
carcinomas, in order to define a relationship between beta-
catenin and EBV and to clarify the impact of beta-catenin
or E-cadherin on the prognosis.
MATERIALS AND METHODS
Patients and tumor tissue
The present study was based on data from 111 Korean
patients undergoing surgically resection for gastric carcino-
mas from 1990 to 1994 at the Seoul National University
Boramae Hospital. Age, sex, tumor size and location, tumor
differentiation according to the WHO classification, Lauren
classification, and pathological tumor stage (TNM stage) ac-
cording to the American Joint Committee on Cancer (AJCC)
system were evaluated. Survival data were obtained from hos-
pital records and patients’ physicians in charge. The overall
survival period of the patients was measured from the date of
operation to the date of death or the last follow-up.
EBER-in situ hybridization
Three micromete thick sections were cut from each paraf-
fin block, deparaffinized and dehydrated, digested with pro-
teinase K, and hybridized for two hours at 37℃ with a flu-
orescein-conjugated EBV oligonucleotide probe targeting
EBV-encoded RNA (EBER) (Novocastra, Newcastle-upon-
Tyne, U.K.). Hybridization products were detected using
an alkaline phosphatase-conjugated antibody to fluorescein
isothiocyanate (affinity-isolated rabbit F[ab′ ]). 5-Bromo-4-
chloro-3-indolylphosphate and nitroblue tetrazolium were
used as an enzyme substrate to demonstrate the alkaline
phosphatase activity. The slides were counterstained with
Mayer’s hematoxylin. Using a light microscope, black or
dark navy-colored aggregates at the hybridization site were
interpreted as positive staining (Fig. 1A). Rare reactive lym-
phocytes showed a positive signal of EBER, but only signals of
EBER within the tumor cells were considered to be positive.
Fig. 1. Representative features of in situ hybridization for Epstein-Barr virus (A) and immunohistochemistry for beta-catenin (B-D) and E-
cadherin (E-F). (A) Most of cancer cell nuclei reveal strong signals of black or dark navy aggregates on in situ hybridization for Epstein-
Barr virus, while normal stroma cell nuclei produce no signal (×200). (B) Beta-catenin shows loss of membranous staining in cancer cells
(left 2/3), while preserved membranous staining in normal epithelium (right 1/3) (×100). (C) Beta-catenin reveals cytoplasmic expression
without nuclear accumulation in cancer cells (×200). (D) Beta-catenin demonstrates nuclear accumulation in cancer cells without cyto-
plasmic expression (×400). (E) E-cadherin discloses loss of membranous staining in cancer cells (right 2/3), while preserved membra-
nous staining in normal epithelium (left 1/3) (×200). (F) E-cadherin exhibits well preserved membranous staining in cancer cells (×200). 
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Immunohistochemistry
Tumor tissue was retrieved from formalin-fixed, paraffin-
embedded specimen. After the antigen retrieval process by
microwave, immunohistochemistry was performed with
monoclonal antibodies against E-cadherin (1:100, Zymed
Laboratories, San Francisco, CA, U.S.A.) and beta-catenin
(1:100, Transduction Laboratories, Lexington, KY, U.S.A.),
using avidin-biotin complex method. For an interpretation
of immunohistochemical staining, cut-off point was adapt-
ed as reported previously (7, 21, 22, 24-26). Those cases with
loss of membranous staining in more than 10% of tumor
cells were considered to be an altered expression of E-cad-
herin protein (7, 24, 25). An altered expression of beta-cate-
nin protein was divided into three patterns, that is, loss of
membranous staining in more than 10% of tumor cells (7,
24, 25), cytoplasmic expression in any degree of tumor cells
(21, 22, 26) and nuclear accumulation in any degree of tumor
cells (21, 22, 26) patterns.
Statistics 
All statistical analyses were conducted using the SPSS 10.0
statistical software program (SPSS, Chicago, IL, U.S.A.). The
chi-square test or Fisher’s exact test (two-sided), Pearson
correlation (two-tailed), and Kendall’s tau-b correlation were
applied. The cumulative survival rates were obtained by the
Kaplan-Meier analysis, and differences in survival were com-
pared using the log-rank test. Multivariate analysis was per-
formed using the Cox proportional hazards model. Values of
p<0.05 were considered to be statistically significant.
RESULTS
Cilnicopathological features 
Clinicopathological features are summarized in Table 1
and 2. The follow-up period ranged from 2 to 167 months,
with a median of 50 months; thirty-five patients (31.5%)
were dead and 76 (68.5%) were alive. Among the clinico-
pathological features evaluated in the present study, Lauren
classification showed correlations with tumor location, lymph
node metastasis (pN stage), TNM stage, and patient’s survival
(p<0.05). 
EBV-infected gastric carcinomas
EBV infection was revealed in seven carcinomas (6.3%)
(Fig. 1A), and none of EBV-infected gastric carcinomas show-
Epstein-Barr virus
Infection p value
n
E-cadherin
Alteration p value
beta-catenin
Alteration p value
Sex 0.31 0.31 0.38
Male 76 6 (8%) 57 (75%) 21 (62%)
Female 35 1 (3%) 23 (66%) 13 (38%)
Age (yr)
Range 26-79 31-67 26-79 26-69
Median 57 62 57 55
Tumor size
Range (cm)  1.0-14.0 2.0-8.0 1.0-14.0 2.0-10.0
Mean (cm) 4.7±2.27 5.6±2.28 4.9±2.44 4.8±2.17
Tumor site 0.15 0.76 0.80
Low 1/3 81 3 (4%) 59 (73%) 25 (31%)
Middle 1/3 29 4 (14%) 20 (69%) 9 (31%)
Upper 1/3 1 0 1 (100%) 0
Lauren 0.16 0.90 0.14
Intestinal 44 1 (2%) 32 (73%) 10 (23%)
Diffuse 67 6 (9%) 48 (72%) 24 (36%)
TNM stage* 0.81 0.75 0.87
I 33 0 25 (76%) 8 (24%)
II 14 2 (14%) 8 (57%) 5 (15%)
IIIA 18 1 (6%) 13 (72%) 6 (18%)
IIIB 13 0 10 (77%) 5 (15%)
IV 33 4 (12%) 24 (73%) 10 (29%)
Patient outcome 0.08 0.98 0.38
Alive 76 7 (9%) 54 (71%) 21 (28%)
Dead 35 0 26 (74%) 13 (37%)
Table 1. Relationship between Epstein-Barr virus infection, beta-catenin alteration or E-cadherin alteration, and clinicopathological fea-
tures in 111 cases of gastric carcinomas
*Pathologic tumor stage according to the American Joint Committee on Cancer system.ed beta-catenin nuclear accumulation. However, five out of
seven EBV-infected carcinomas revealed beta-catenin alter-
ation; three cases showed cytoplasmic expression, and two out
of these three cases had loss of membranous staining simul-
taneously. Another two cases revealed loss of membranous
staining. Regarding E-cadherin, only one EBV-infected car-
cinoma disclosed E-cadherin alteration. However, there were
no statistical significances in beta-catenin or E-cadherin
immunoexpression patterns between EBV-infected gastric
carcinomas and non-infected carcinomas (Table 3).
The EBV infection status showed a marginal impact on
the patient outcome (p=0.08) (Table 2) but was not associat-
ed with beta-catenin or E-cadherin alteration. 
Expression of beta-catenin and E-cadherin
There were no significant relationships between clinico-
pathological features and immunoexpresssion of beta-catenin
or E-cadherin (Table 2, 3). A representative immunohisto-
chemical staining pattern is shown in Fig. 1B-F. In normal
gastric epithelium, both E-cadherin and beta-catenin show-
ed cytoplasmic membranous staining (Fig. 1B, E). Eighty
cases (72.1%) showed beta-catenin alteration, i.e. loss of mem-
brane staining in 65 cases (58.6%), cytoplasmic expression
in 35 cases (31.5%), and nuclear accumulation in 15 cases
(13.5%) (Table 1, 2). Regarding concurrent cytoplasmic
and nuclear beta-catenin expression, nine of 35 cases display-
ed both cytoplasmic and nuclear beta-catenin. In six addi-
tional cases (5.4%), beta-catenin was seen only in the nuclei,
leading to a total of 15 cases (13.5%) with beta-catenin nucle-
ar accumulation. E-cadherin alteration (loss of membrane
staining) was observed in 34 cases (30.6%) of gastric carci-
nomas.
The E-cadherin alteration was statistically significantly
correlated with beta-catenin alteration (p=0.003); in partic-
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beta-catenin alteration
Membranous
loss (%)
p value
n Cytoplasmic 
expression (%)
p value Nuclear accu-
mulation (%)
p value
Sex 0.84 0.65 0.10
Male 76 45 (59%) 25 (33%) 13 (17%)
Female 35 20 (57%) 10 (29%) 2 (6%)
Age (yr)
Range 26-79 26-79 26-76 36-69
Median 57 56 57 53
Tumor size
Range (cm)  1.0-14.0 1.0-10.0 1.0-14.0 1.5-14.0
Mean (cm) 4.7±2.27 4.8±2.30 5.1±2.45 5.5±3.40
Tumor site 0.65 0.74 0.77
Low 1/3 81 48 (59%) 25 (31%) 12 (15%)
Middle 1/3 29 16 (55%) 10 (34%) 3 (10%)
Upper 1/3 1 1 (100%) 0 0
Lauren 0.76 0.96 0.55
Intestinal 44 25 (57%) 14 (32%) 7 (16%)
Diffuse 67 40 (58%) 21 (31%) 8 (12%)
TNM stage* 0.66 0.16 0.85
I 33 22 (67%) 7 (21%) 4 (12%)
II 14 6 (43%) 5 (36%) 3 (21%)
IIIA 18 10 (56%) 9 (50%) 2 (11%)
IIIB 13 8 (61%) 2 (35%) 1 (8%)
IV 33 19 (58%) 12 (36%) 5 (15%)
Patient outcome 0.36 0.86 0.08
Alive 76 46 (61%) 23 (30%) 8 (11%)
Dead 35 19 (54%) 12 (34%) 7 (2%)
Table 2. Relationship between three altered patterns of beta-catenin expression and clinicopathological features in 111 cases of gas-
tric carcinomas
*Pathologic tumor stage according to the American Joint Committee on Cancer system.
EBV-infected 
cases 
(n=7) (%)
Non-infected 
cases
(n=104) (%) 
p
value
beta-catenin alteration 5 (71%) 75 (72%) 0.97
Membranous loss 3 (43%) 62 (60%) 0.38
Cytoplamic expression 3 (43%) 32 (31%) 0.50
Nuclear accumulation 0 15 (14%) 0.28
E-cadherin alteration 1 (14%) 33 (32%) 0.33
(membranous loss)
Table 3. Comparison of beta-catenin and E-cadherin immuno-
expression between Epstein-Barr virus (EBV)-infected gastric
carcinomas and non-infected carcinomasular, with beta-catenin membranous loss or nuclear accumu-
lation (p=0.012 and p=0.040, respectively) (Table 4). 
Survival analyses
The beta-catenin nuclear accumulation was associated with
a poor patient survival in a subset of Lauren diffuse-type car-
cinomas. Additionally, in a subset of male patients, beta-ca-
tenin nuclear accumulation and E-cadherin alteration were
related to a poor patient survival (p<0.05).
The combined expression pattern of beta-catenin/E-cad-
herin was reclassified into four combinations (considering
Table 4); the combination of beta-catenin alteration/E-cad-
herin, the combination of beta-catenin membranous pattern/
E-cadherin, the combination of beta-catenin cytoplasmic
pattern/E-cadherin, and the combination of beta-catenin
nuclear pattern/E-cadherin. On univariate analysis, the com-
bination of beta-catenin nuclear pattern/E-cadherin had a
significant impact on the patient survival (p<0.05) (Fig. 2A).
In other words, a group with beta-catenin nuclear accumu-
lation/E-cadherin alteration showed poor patient survival.
Elaborating on this, in groups of combined beta-catenin
nuclear pattern/E-cadherin, the patient survival rate of each
group was 63% in beta-catenin nuclear accumulation/E-
cadherin alteration, which contrasted with the remaining
groups; 29%, 29%, and 21%, in a group with beta-catenin
nuclear accumulation/normal E-cadherin, in a group with
beta-catenin, no nuclear accumulation/normal E-cadherin,
and in a group with beta-catenin, no nuclear accumulation/
E-cadherin alteration, respectively (Fig. 2A). 
On multivariate analysis, the combined beta-catenin nu-
clear pattern/E-cadherin, and cancer stage (TNM classifica-
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E-cadherin expression
No alteration Alteration
p
value
beta-catenin 0.003
No alteration 28 3
Alteration 49 31
beta-catenin membranous  0.012
Preservation 39 7
Loss 38 27
beta-catenin cytoplasmic  0.312
No expression  55 21
Expression 22 13
beta-catenin nuclear  0.040
No accumulation 70 26
Accumulation 7 8
Table 4. Relationship between E-cadherin and beta-catenin ex-
pression in 111 cases of gastric carcinomas
Fig. 2. Kaplan-Meier survival plots. Combined immunoexpression of beta-catenin nuclear pattern/E-cadherin (A), TNM tumor stage (B),
and beta-catenin nuclear accumulation (C). (A) Group 4 (with a combined pattern of beta-catenin nuclear accumulation/E-cadherin alter-
ation) shows a poor patient survival (p=0.001). Group 1, a group with a combined pattern of beta-catenin no nuclear accumulation/nor-
mal E-cadherin; Group 2, beta-catenin nuclear accumulation/normal E-cadherin; Group 3, beta-catenin no nuclear accumulation/E-cad-
herin alteration; and Group 4, beta-catenin nuclear accumulation/E-cadherin alteration. (B) Advanced TNM tumor stage group has a lower
rate of patient survival (p=0.008). (C) Beta-catenin nuclear accumulation group has a marginal impact on the patient survival (p=0.077).
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*Group 1, a group with combined pattern of beta-catenin, no nuclear
accumulation/normal E-cadherin; Group 2, beta-catenin nuclear accu-
mulation/normal E-cadherin; Group 3, beta-catenin, no nuclear accu-
mulation/E-cadherin alteration; Group 4, beta-catenin nuclear accumu-
lation/E-cadherin alteration.
AJCC, American Joint Committee on Cancer.
Prognostic factors Hazard ratio 
(95% confidence interval)
p
value
TNM stage (AJCC system) 0.001
II vs. I 1.044 (0.083-13.074)
IIIA vs. I 9.095 (1.440-57.461)
IIIB vs. I 14.923 (3.220-69.158)
IV vs. I 22.371 (4.132-121.130)
Combined pattern of beta-catenin 0.008
nucleus staining/ E-cadherin
*Group 2 vs. Group 1 1.006 (0.178-5.688)
Group 3 vs. Group 1 0.352 (0.092-1.350)
Group 4 vs. Group 1 5.492 (1.621-18.601)
Table 5. Multivariate analysis of the prognostic factors for over-
all survival (Cox proportional hazards model) in the 111 patients
with gastric carcinomastion based on the AJCC system) had significant impacts on
patient survival (p=0.008 and p=0.001, respectively) (Table
5, Fig. 2). Besides, beta-catenin nuclear accumulation showed
a marginal impact (p=0.077) (Fig. 2C).
DISCUSSION
In the present study, we suggest that beta-catenin activa-
tion through nuclear accumulation seldom occurs in EBV-
infected gastric carcinomas, although beta-catenin expres-
sion can be altered in patterns of membranous loss and cyto-
plasmic expression. Furthermore, our previous paper showed
that NFkappaB nuclear accumulation occurred more fre-
quently in EBV-infected gastric carcinomas than in EBV-
negative gastric carcinomas (p<0.05) (10), suggesting EBV-
infection could be related to NFkappaB activation. The beta-
catenin cytoplasmic stabilization is involved in the first step
of beta-catenin activation, and nuclear transport is the sec-
ond step (27), In the present study, it was not certain whether
cytoplasmic expression might be related to activated form
of beta-catenin or not, because we have not evaluated the
free beta-catenin level in cytoplasm or beta-catenin-depen-
dent gene expression level. However, beta-catenin nuclear
accumulation can represent beta-catenin activation. Conse-
quently, in EBV-infected gastric carcinomas, beta-catenin
activation through nuclear accumulation hardly occurs, but
NF- kappaB could be activated. It is plausible that NFkap-
paB activation might suppress beta-catenin activation in
EBV-infected gastric carcinomas because previous papers
suggest that beta-catenin activation can inhibit NFkappaB
activation (9). Therefore, a negative crosstalk between beta-
catenin and NFkappaB activation seems to exist in EBV-
infected gastric carcinomas.
In the present study, E-cadherin alteration (loss of mem-
brane staining) was observed in 30.6% and beta-catenin
alteration in 72.1% [loss of membrane staining in 58.6%,
cytoplasmic expression in 31.5%, and nuclear staining in
13.5%] of gastric carcinomas. The figures of the E-cadherin
alteration and beta-catenin nuclear accumulation are almost
same as those in the paper by Grabsch et al., 30.7% and 13.2%,
respectively (21). Additionally, the figures of the beta-catenin
membranous loss, cytoplasmic expression and nuclear accu-
mulation are similar to those in the paper by Nabais et al.
(22, 26). Meanwhile, concerning beta-catenin, some studies
did not evaluate nuclear accumulation of beta-catenin (5, 6,
8, 23, 28). However, beta-catenin nuclear accumulatin should
be evaluated in the study of the Wnt signal activation be-
cause beta-catenin translocated into the nucleus is predomi-
nantly in an active and oncogenic form (11, 27, 29, 30). The
Wnt signal activation induces beta-catenin stabilization and
its accumulation in the cytoplasm, and then, beta-catenin is
translocated to the nucleus, where it interacts with DNA
binding proteins of the T-cell factor-lymphoid enhancer fac-
tor (Tcf/LEF) family, causing transcriptional activation of
target genes (11, 27, 29, 30), such as c-myc and cyclin D1
oncogenes (13). Moreover, in the present study and others
(26), certain cases showed beta-catenin only in the nuclear
accumulation pattern, neither in cytoplasmic expression nor
membranous loss. Therefore, beta-catenin nuclear accumu-
lation should be assessed necessarily.
In the multivariate survival analysis, a group with com-
bined beta-catenin nuclear accumulation/E-cadherin alter-
ation showed a poor patient survival, compared to the other
groups (Fig. 2A). In this combined pattern, oncogenic pro-
cess by beta-catenin activation and cancer progression due
to reduction of the cell-cell adhesion by E-cadherin loss can
occur together and end up with a poor patient survival, accord-
ingly. This result might apparently support previous sugges-
tions that the beta-catenin or E-cadherin immunoexpression
pattern correlates with patient survival (5-8), but the pre-
sent study showed that only beta-catenin nuclear accumula-
tion or only E-cadherin alteration had no significant impact
on patient survival, or rather a combined pattern of beta-
catenin nuclear accunmulation/E-cadherin alteration was an
independent prognostic factor.
There have been controversies concerning the prognostic
significance of E-cadherin or bata-catenin in gastric cancer;
that is, Grabash et al. (21), Nabias et al. (22), and Joo et al.
(23) showed no prognostic significance in their studies. This
discrepancy might be partly due to the interpretation of
immunohistochemical staining or case selection bias. First,
we can find a fault with ignorance of beta-catenin nuclear
accumulation in some papers (5, 6, 8, 23, 28). Secondly, sub-
sets of cases can make wide differences. For example, in the
present study, beta-catenin nuclear accumulation or E-cad-
herin alteration had a significant impact on patient survival
in subsets such as Lauren diffuse-type patients and male pa-
tients, but a marginal impact in the total patient group as a
whole. Additionally, Nabais et al. demonstrated that beta-
catenin or E-cadherin did not have a prognostic significance
based upon different subsets of gastric carcinomas (22). 
Previous studies analyzed the prognostic significance of
each protein, beta-catenin or E-cadherin, rather than the
combined pattern of beta-catenin/E-cadherin. To the best of
our knowledge, there is a study about the combined exp-
ression pattern of beta-catenin/E-cadherin, in which it cor-
related with the patient survival in univariate analysis, but
not in multivariate analysis (23), although it could be a crit-
ical drawback that beta-catenin nuclear accumulation was
not analyzed in their study (23). Besides, the other combined
pattern of abnormal E-cadherin/MUC1-positive was suggest-
ed to be an unfavorable prognostic factor (8). 
In conclusion, beta-catenin expression can be altered in EBV-
infected gastric carcinomas, but beta-catenin activation through
nuclear accumulation hardly occurrs. The beta-catenin and
E-cadherin alterations correlated with each other. The com-
bined beta-catenin and E-cadherin pattern can be used as pro-
860 I.M. Jung, J.K. Chung, Y.A. Kim, et al.gnostic markers in Korean gastric carcinomas, and frequent
alterations of beta-catenin and E-cadherin proteins are observed.
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